Identification Problem in Pharmacokinetic Model for the Treatment of Type II Diabetes Mellitus Using Metformin

access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Type II diabetes mellitus is a metabolic disorder in which a person has highly elevated blood glucose levels resulting from bodily tissues be-ing resistant to the insulin that is produced in the pancreas. Metformin is an anti-hyperglycemic drug that is widely used for treating type II diabetes mellitus. Metformin works to reduce blood glucose levels by decreasing the rate of hepatic glucose output, decreasing the rate of in-testinal glucose absorption, and increasing the rate of glucose uptake by 1510 Narayan Thapa, Kowan O’Keefe and Michal Gudejko muscle cells and fat tissue. In this work, an identification problem was investigated using an existing pharmacokinetic compartmental model for type II diabetes mellitus where the effects of oral administration of metformin are considered. The parameters of the model were estimated